Benicar Monotherapy

Benicar goes the distance with the power to help patients reach their BP goals:

• Benicar monotherapy provides significant mean blood pressure (BP) reductions vs. baseline at the starting dose of 20 mg once-daily.
• Benicar 40 mg once-daily provides additional mean BP reductions versus baseline.

On this page:

Power to help safely achieve normal BP in mild patients
Benicar in patients with mild-to-moderate hypertension
Helping patients reach JNC 7 goal or lower
Benicar in more challenging patients
Continuous 24-hour coverage
References

Power to help safely achieve normal BP in mild patients

Over 80% of patients with mild hypertension (mean baseline 151/90 mm Hg) reached their goal of BP <140/90 mm Hg in a double-blind, placebo-controlled study (cumulative goal attainment: 81%; placebo: 43%).¹

Additionally, over 60% of patients achieved the more aggressive goal of BP <130/80 mm Hg (60.3%; placebo: 7%) and nearly 45% achieved normotension, which is defined by JNC 7 as <120/80 mm Hg (44.8%; placebo: 1%).¹

For the patients achieving normotension, the mean SPB drop experienced was 31/17 mm Hg.¹ Mean BP baseline for patients who achieved <120/80 mm Hg: 148/89 mm Hg (placebo mean drop: 19/4 mm Hg).

A total of 276 patients were included in the 15-16-week, double-blind, placebo-controlled BeniFORCE trial with 130 of the patients having Stage 1 hypertension. Following a 3-4-week placebo run-in period, patients were randomized to placebo (12 weeks) or Benicar 20 mg (3 weeks). If SBP remained >120 mm Hg or DBP remained >80 mm Hg, patients were titrated at 3-week intervals until BP was normalized as follows: Benicar 40 mg, Benicar HCT 40 mg/12.5 mg, and Benicar HCT 40 mg/25 mg. Patients with BP <120/80 mm Hg at any visit continued with their currently assigned therapy.¹
See study description

Back to top

Benicar in patients with mild-to-moderate hypertension
Benicar monotherapy provides significant BP reductions — beginning at the starting dose of 20 mg once-daily:^{1, 2}

• Studies show that Benicar 20 mg — the usual recommended starting dose — resulted in significant mean reductions vs. baseline at trough in systolic and diastolic blood pressure of up to 15/12 mm Hg (mean placebo reductions of 6/6 mm Hg).²
• Benicar 40 mg resulted in significant mean reductions vs. baseline at trough in systolic and diastolic blood pressure of up to 18/13 mm Hg (mean placebo reductions of 6/6 mm Hg).²
• Doses above 40 mg do not appear to have greater effect.¹

For a detailed study description, see the Monotherapy Clinical Trials section.

Back to top

Helping patients reach JNC 7 goal or lower
Nearly 40% of patients with mild-to-moderate hypertension taking Benicar 40 mg reached their goal of BP <140/90 mm Hg at Week 8 (goal attainment: 39.7%; placebo: 12.4%).*¹ Additionally, over 27% of patients with mild-to-moderate hypertension taking Benicar 20 mg reached their goal of BP <140/90 mm Hg at Week 4 (goal attainment: 27.4%; placebo: 10.3% ).*¹

14.7% of patients on Benicar 40 mg monotherapy reached the more aggressive goal of BP <130/85 mm Hg at Week 8 (placebo: 1.1%).*¹

*Week 4 and Week 8 cuff BP control results (secondary analysis, n=643, patients with available observation at visit) of the Benicar arm of a 12-week, randomized, double-blind, multicenter, forced-titration study (n=696, intent-to-treat population) investigating the efficacy and safety of Benicar in patients with Stage 2 hypertension. The primary endpoint was mean cuff DBP reductions at Week 8. In this study, 22% of placebo patients were African American.¹

Back to top

Benicar in more challenging patients
Benicar provides proven BP reductions in patients with higher baseline SBP — beginning at the starting dose.³ Benicar 20 mg/day reduced mean SBP by 16.9 mm Hg (P<.001 vs. baseline), and there were further dose-dependent decreases in mean SBP to a maximum of 35 mm Hg with Benicar HCT 40/25 mg/day.

For a detailed study description, see the BENISYS Clinical Trial section.

Back to top

Continuous 24-hour coverage
Benicar provides BP reductions maintained over 24 hours at the 20 mg starting dose.¹

† 24 hour coverage ABPM Study: Results from 20 mg once-daily ABPM component, n=39. Part of an 8-week, randomized, double-blind, placebo-controlled, parallel-group study, N=289. Assessment of Benicar efficacy and safety of patients with hypertension.⁵

Back to top